Skip to main content

Table 3 Associations of both coronary artery disease and high-sensitivity cardiac troponin T with major adverse cardiovascular events

From: Combined evaluation of coronary artery disease and high-sensitivity cardiac troponin T for prediction of adverse events in patients with hypertrophic cardiomyopathy

  NCA, normal hs-cTnT (n = 54) CAD, normal hs-cTnT (n = 23) NCA, elevated hs-cTnT (n = 53) CAD, elevated hs-cTnT (n = 32)
MACEs (n) 5 2 7 10
Person-years 246.8 90.4 199.3 95.8
Incidence rate (95% CI)a 2.0 (0.3–3.8) 2.2 (0.0–5.2) 3.5 (1.0–6.1) 10.4 (4.3–16.6)
Unadjusted HR (95% CI), P 1 1.1 (0.2–5.7), 0.908 1.9 (0.6–6.0), 0.287 5.5 (1.8–16.8), 0.003
Adjusted HR (95% CI), P
Model 1 1 0.6 (0.1–3.3), 0.526 1.6 (0.5–5.2), 0.436 3.4 (1.0–11.1), 0.044
Model 2 1 0.5 (0.1–3.4), 0.521 1.6 (0.5–5.1), 0.461 3.7 (1.0–13.1), 0.046
Model 3 1 0.6 (0.1–4.6), 0.664 1.9 (0.5–7.1), 0.322 5.7 (1.3–24.1), 0.018
Model 4 1 0.5 (0.1–3.9), 0.542 1.2 (0.3–5.2), 0.765 Model 1 with adjustment for age and gender5.0 (1.0–23.8), 0.046
  1. Model 1 with adjustment for age and gender
  2. Model 2 with adjustment for model 1 plus symptoms and comorbidities, including chest pain, palpitations, syncope/pre-syncope, dyspnea, hypertension, diabetes and atrial fibrillation
  3. Model 3 with adjustment for model 2 plus devices, procedures and medications, including aspirin, warfarin, statins and beta-blocker
  4. Model 4 with adjustment for model 3 plus echocardiographic parameters, including LVEDD, LA diameter, MWT, LVEF and LVOT obstruction
  5. CI confidence interval, HR hazard ratio; other abbreviations as in Tables 1 and 2
  6. aPer 100 person-years